Characteristics | All cohort (n = 146) |
---|---|
Age, y, median. (IQR) | 60 (54–66.25) |
Sex, no. (%) | |
Male | 113 (77.4) |
Female | 33 (22.6) |
BMI, kg/m2, median. (IQR) | 23.87 (21.44–26.65) |
Symptom at presentation, no. (%) | |
Absent | 38 (26) |
Present | 108 (74) |
ASA score, no. (%) | |
I–II | 129 (88.3) |
III | 17 (11.7) |
Surgical approach, no. (%) | |
Open | 59 (40.4) |
Laparoscopic | 87 (59.6) |
Surgical time, min, median. (IQR) | 305.5 (224.25–400) |
Blood loss, ml, median. (IQR) | 600 (200–1650) |
Transfusion, no. (%) | 61 (41.8) |
Segmental resection of vena cava, no. (%) | 27 (18.5) |
Tumour side, no. (%) | |
Left | 52 (35.6) |
Right | 94 (64.4) |
Tumour size, cm, median. (IQR) | 8.25 (6.48–10) |
Tumour thrombus level, no. (%) | |
0–II | 118 (80.8) |
III–IV | 28 (19.2) |
Invasion of venous wall, no. (%) | 53 (41.4) |
Histology subtype, no. (%) | |
Clear cell | 124 (84.9) |
Non-CCRCC | 22 (15.1) |
Nuclear grade, no. (%) | |
I–II | 61 (41.7) |
III–IV | 85 (58.3) |
lymph node metastasis, no. (%) | 9 (5.9) |
Necrosis, no. (%) | 66 (45.8) |
SSIGN score | |
Low-risk (score 2–4) | 49 (33.5) |
Intermediate-risk (score 5–7) | 76 (52.1) |
High-risk (score 8–11) | 21 (13.4) |